New combo therapy aims to wipe out CLL cells in untreated patients
NCT ID NCT05336812
First seen Feb 19, 2026 · Last updated Jun 19, 2026 · Updated 16 times
Summary
This phase 2 trial tests two different drug combinations in people with untreated chronic lymphocytic leukemia (CLL). Participants first take acalabrutinib alone, then are randomly assigned to add either obinutuzumab or venetoclax. The goal is to see which combination better eliminates cancer cells from the bone marrow, potentially leading to longer remission. The study enrolls 52 adults who have not received prior CLL treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ohio State University Comprehensive Cancer Center
RECRUITINGColumbus, Ohio, 43210, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
acalabrutinib, obinutuzumab, venetoclax
What this could lead to
If successful, this could point toward a more effective combination therapy for untreated CLL, potentially leading to longer remission without the need for continuous treatment.
What could go wrong
This is an early phase 2 trial with only 52 participants, so results may not apply to all patients. Side effects from the drug combinations are possible, and the study may not show a clear benefit over existing treatments.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.